Tech Company Financing Transactions
Centivax Funding Round
Centivax, based in San Francisco, raised $45 million from private investors, Amplify Partners and Bold Capital Partners.
Transaction Overview
Company Name
Announced On
7/9/2025
Transaction Type
Venture Equity
Amount
$45,000,000
Round
Series A
Investors
private investors (Lead Investor) (Steve Jurvetson)
Proceeds Purpose
The company intends to use the funds to accelerate its first clinical candidate, a universal flu vaccine currently in CMC development, through a Phase I clinical trial slated to begin within eight months.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
329 Oyster Point Boulevard South
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Undisclosed
Website
Email Address
Overview
Developer of a therapeutics and clinical-stage company intended to treat and eradicate rapidly mutating pathogens. The company applies its computational immune engineering expertise to develop therapeutic monoclonal antibodies against a variety of targets, it builds a panel of neutralizing antibodies against SARS-CoV-2, enabling people to be safe from health issues with the help of vaccinations.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jacob Glanville
Chief Operating Officer
David Tsao
Chief Technical Officer
Nicholas Bayless
Co-Founder
Sawsan Youssef
Browse more venture capital transactions:
Prev: 7/9/2025: Vytalize Health venture capital transaction
Next: 7/9/2025: OllyGarden venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. All VC database entries reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs